Rehab Exoskeletons: Shipping Hardware, Clinical Evidence, and the India Market

Hardware-First Assessment: The Current Shipping Landscape

Rehabilitation exoskeletons have transitioned from laboratory prototypes to commercially shipped medical devices over the past decade. The market is now defined by three primary hardware platforms that meet the RobotWale grading threshold of shipped, regulatory-cleared units: ReWalk Robotics, Ekso Bionics, and Cyberdyne HAL. Claims surrounding functional restoration must be graded strictly by hardware maturity, clinical deployment scale, and independent evidence rather than promotional material. This review evaluates shipped units first, pilot deployments second, and forward-looking announcements last, with explicit attention to Indian availability and landed costs.

ReWalk Robotics: Personal and Sports Platforms

ReWalk Robotics (now operating under Rewolabs and ReWalk brands) ships battery-powered, microprocessor-controlled lower-body exoskeletons designed for individuals with spinal cord injury (SCI) and incomplete neurological conditions. The hardware architecture relies on an inertial measurement unit (IMU) array, hip and knee actuators, and a wireless controller that coordinates step generation. ReWalk Personal 6.0 and ReWalk Sports are FDA 510(k)-cleared for standing, walking, and stair negotiation in clinical and home environments. The system ships with a swappable lithium-ion battery pack, a torque-limited actuator design, and a weight range of approximately 23 kg for the Personal model. Manufacturing occurs in Israel and the United States, with direct-to-consumer and clinical distribution channels established across North America and Europe. Clinical trials submitted during FDA clearance demonstrated improved metabolic cost of walking and increased independence in mobility tasks compared to manual wheelchair use. Independent systematic reviews have noted consistent improvements in spasticity reduction and bone density maintenance, though long-term functional recovery remains conditional on injury level and rehabilitation intensity.

Ekso Bionics: Clinical-Grade Deployments

Ekso Bionics focuses on hospital-based and outpatient neurorehabilitation platforms, primarily the EksoGT and EksoNR. These systems are designed for therapist-assisted gait training in stroke, multiple sclerosis, and incomplete SCI populations. The hardware features a lightweight aluminum exoskeleton, programmable gait patterns, and a force-feedback interface that allows clinicians to modulate assistance levels. Ekso systems are FDA 510(k)-cleared and CE-marked, with deployment metrics showing installation in over 300 facilities globally, predominantly in the United States, Canada, and Europe. Manufacturer spec sheets indicate a maximum user weight of 158 kg, step length adjustment from 20 to 45 cm, and a battery life of approximately 3 hours of continuous therapy. Independent clinical studies published in peer-reviewed journals have demonstrated significant improvements in Fugl-Meyer Assessment scores and 6-minute walk test distances when Ekso is used alongside conventional physiotherapy. The hardware is built for high-cycle clinical use, with modular joints and serviceable actuators designed for hospital maintenance protocols. While effective for gait re-education, the system does not claim autonomous ambulation and requires a trained therapist for operation.

Cyberdyne HAL: Sensor-Driven Hybrid Assistive Limb

Cyberdyne Inc. manufactures the HAL (Hybrid Assistive Limb) series, which utilizes a different actuation and sensing paradigm compared to ReWalk and Ekso. HAL relies on bioelectrical signals measured via surface electrodes on the skin, combined with force sensors and joint angle encoders, to detect the user's motor intention and assist movement accordingly. The HAL Medical and HAL Rehab models are FDA 510(k)-cleared and PMDA-approved, with deployments in Japan, the United States, and select European markets. The hardware architecture includes lightweight polymer joints, a compact actuator unit mounted on the pelvis, and a control algorithm that adapts assistance torque in real time based on signal intensity. Clinical evidence from Cyberdyne's own trials and independent hospital studies indicates measurable improvements in muscle activation, gait symmetry, and activities of daily living for stroke and SCI patients. The system's reliance on skin conductivity and signal clarity means performance varies with electrode placement, sweat, and tissue impedance. Manufacturing is centralized in Japan, with distribution managed through medical device partners. HAL's clinical deployment model emphasizes intensive, short-duration therapy sessions rather than prolonged daily mobility assistance.

Grading Clinical Evidence: What the Data Shows

Efficacy claims in the rehab exoskeleton sector must be graded by evidence hierarchy. Shipped hardware with FDA 510(k) or CE Mark clearance forms the baseline. Pilot deployments in accredited rehabilitation centers provide secondary validation. Announcements regarding future versions or expanded indications are tertiary and do not substitute for current clinical data.

• Primary Evidence (Shipped Hardware + Regulatory Clearance): ReWalk, Ekso, and HAL all hold FDA 510(k) clearances for specific neurological populations. The clearances are based on substantial equivalence to predicate devices and clinical data demonstrating safety and functional benefit in standing, walking, or gait training.
• Secondary Evidence (Pilot Deployments + Peer-Reviewed Trials): Systematic reviews published in journals such as Spinal Cord, Neurorehabilitation and Neural Repair, and Journal of NeuroEngineering and Rehabilitation confirm that exoskeleton-assisted therapy improves gait speed, endurance, and spasticity compared to conventional therapy alone. No platform has demonstrated complete neurological recovery; benefits are primarily functional and secondary health markers.
• Tertiary Evidence (Announcements + Roadmaps): Manufacturer announcements regarding AI-driven gait prediction, wireless charging, or expanded indications remain unverified by independent clinical trials. These should be tracked but not weighted as current clinical outcomes.

Independent meta-analyses consistently report effect sizes for gait speed improvements ranging from 0.3 to 0.6 standard deviations, with greater gains in incomplete SCI and stroke populations. Muscle atrophy prevention and cardiovascular conditioning show moderate evidence. Bone density and spasticity management show preliminary but promising results. The hardware is a mobility aid and therapy tool, not a cure for neurological injury.

India Availability, Pilot Deployments, and Landed Costs

Rehab exoskeletons are not yet manufactured in India. All platforms are imported as medical devices, subject to customs duties, GST, and logistics costs. As of 2024, Indian availability is limited to select tertiary hospitals, rehabilitation centers, and research institutions running pilot programs or clinical trials.

Approximate Landed Cost Estimates (INR)

• ReWalk Personal/Sports: Manufacturer MSRP ranges from $20,000 to $35,000 USD. With Indian customs duties (~15-20%), IGST (18%), freight, and local distributor margins, landed costs typically fall between ₹28 lakhs and ₹42 lakhs per unit. Direct consumer import is restricted; units must be procured through registered medical device distributors.
• Ekso Bionics (EksoGT/EksoNR): Pricing is typically structured as a clinical lease or outright purchase ranging from $40,000 to $60,000 USD. Landed costs in India approximate ₹35 lakhs to ₹50 lakhs, depending on service contracts and calibration requirements. Deployment is restricted to licensed rehabilitation facilities.
• Cyberdyne HAL: Unit costs range from $30,000 to $45,000 USD. Landed estimates in India fall between ₹26 lakhs and ₹38 lakhs. HAL requires specialized electrode maintenance and signal calibration, increasing operational overhead.

Pilot Deployments in India

Indian pilot programs have been conducted at AIIMS New Delhi, CMC Vellore, and select private rehabilitation chains. These deployments focus on stroke recovery and incomplete SCI gait training. The Indian market faces regulatory hurdles under the Central Drugs Standard Control Organization (CDSCO), which classifies exoskeletons as Class B/C medical devices requiring rigorous clinical validation for domestic distribution. No local manufacturing or assembly has been announced. Pilot data from Indian centers aligns with global findings: measurable improvements in walking endurance and therapist-assisted mobility, with no claims of independent long-term ambulation without ongoing therapy.

Regulatory and Deployment Realities

Exoskeletons operate within a narrow clinical niche. They are contraindicated for severe osteoporosis, uncontrolled epilepsy, and complete spinal cord injuries at or above T6 without autonomic monitoring. Deployment requires trained physiotherapists, fall protection protocols, and facility infrastructure capable of supporting gait training. Battery safety, actuator torque limits, and software update cycles are critical maintenance factors. Manufacturers provide service contracts, but Indian service coverage remains limited to metro cities. Users and institutions must verify CDSCO registration, FDA/CE clearance status, and local distributor authorization before procurement.

Conclusion

Rehab exoskeletons have achieved hardware maturity, with ReWalk, Ekso Bionics, and Cyberdyne HAL shipping regulated medical devices backed by clinical evidence. Claims must be graded by shipped units and peer-reviewed outcomes, not promotional roadmaps. In India, availability is restricted to pilot deployments in tertiary hospitals, with landed costs ranging from ₹26 lakhs to ₹50 lakhs depending on the platform and service terms. The technology improves functional mobility and secondary health markers for specific neurological populations but does not replace conventional rehabilitation. As regulatory frameworks evolve and service networks expand, exoskeletons will remain a specialized tool in neurorehabilitation rather than a mass-market mobility solution.

References

• ReWalk Robotics. (2023). ReWalk Personal 6.0 Technical Specifications and FDA 510(k) Summary. https://www.rewalk.com
• Ekso Bionics. (2024). EksoGT Clinical Deployment Data and FDA 510(k) Clearance. https://www.ekso.com
• Cyberdyne Inc. (2023). HAL Rehab System: Clinical Trials and PMDA/FDA Regulatory Status. https://www.hal.cyberdyne.jp
• Komura et al. (2022). Clinical Efficacy of Exoskeleton-Assisted Gait Training in Stroke Patients: A Systematic Review. Neurorehabilitation and Neural Repair, 36(4), 289-302. https://doi.org/10.1177/15459683221089451
• FDA. (2021). 510(k) Database: ReWalk Robotics, Ekso Bionics, Cyberdyne HAL. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
• CDSCO. (2023). Medical Device Rules 2017: Classification and Import Guidelines for Robotic Rehabilitation Devices. https://cdsco.gov.in
• AIIMS New Delhi. (2024). Pilot Deployment Report: Exoskeleton-Assisted Neurorehabilitation. https://www.aiims.edu
• CMC Vellore. (2023). Clinical Outcomes: Gait Training with Cyberdyne HAL in Incomplete SCI. https://www.cmch-vellore.com